Document Detail


Normal dynamic MRI enhancement patterns of the upper abdominal organs: gadoxetic acid compared with gadobutrol.
MedLine Citation:
PMID:  19843748     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: The purpose of this study was to investigate whether, at dynamic MRI of the upper abdominal organs, contrast enhancement with gadoxetic acid, a hepatobiliary contrast agent, is comparable with that achieved with an extracellular contrast agent. SUBJECTS AND METHODS: Dynamic gadoxetic acid-enhanced MRI of the pancreas, spleen, kidney, liver, and abdominal aorta was performed on 50 patients; dynamic gadobutrol-enhanced MRI was performed on a control group of 50 patients; and the images were compared. Dynamic imaging with a T1-weighted volumetric interpolated breath-hold examination gradient-echo sequence (TR/TE, 3.35/1.35; flip angle, 12 degrees ) was performed before and 20 (arterial phase), 55 (portal venous phase), and 90 (hepatic venous phase) seconds after bolus injection of gadoxetic acid (0.25 mmol/mL) or gadobutrol (1.0 mmol/mL). Signal-to-noise ratios and enhancement indexes were calculated for each organ and time. RESULTS: All MR images in both groups were of diagnostic quality. During the early dynamic phases, significantly lower mean enhancement indexes were found in the gadoxetic acid group than in the gadobutrol group in the pancreas (portal venous phase, 0.66, 1.39, p <or= 0.001; hepatic venous phase, 0.51, 1.36, p <or= 0.001), spleen (portal venous phase, 1.54, 2.41, p <or= 0.001; hepatic venous phase, 1.19, 2.23, p <or= 0.001), renal cortex (portal venous phase, 1.76, 2.63, p <or= 0.001; hepatic venous phase, 1.60, 2.63, p <or= 0.001), and liver (portal venous phase, 0.76, 0.94, p = 0.016; hepatic venous phase, 0.76, 1.04, p <or= 0.001). In the abdominal aorta, the mean enhancement index was greater after bolus injection of gadoxetic acid (arterial phase, 3.33, 2.24, p <or= 0.005). CONCLUSION: Early dynamic MRI of the upper abdominal organs, especially the spleen, pancreas, and kidney, benefits from the higher gadolinium concentration of gadobutrol than in the organ-specific contrast agent gadoxetic acid. Higher protein binding resulting in increased relaxivity of gadoxetic acid compensates for the low gadolinium concentration in the abdominal aorta.
Authors:
Jens-Peter Kühn; Katrin Hegenscheid; Werner Siegmund; Claus-Peter Froehlich; Norbert Hosten; Ralf Puls
Related Documents :
1871908 - Static and dynamic radionuclide imaging in the diagnosis of the acute scrotum.
1410358 - Spleen: dynamic enhancement patterns on gradient-echo mr images enhanced with gadopente...
20928868 - Automated macrovessel artifact correction in dynamic susceptibility contrast magnetic r...
20512888 - Dynamic contrast-enhanced mr imaging for differentiation of rounded atelectasis from ne...
17923508 - Pulmonary nodules: interscan variability of semiautomated volume measurements with mult...
18493358 - Fiberscopic imaging of the pediatric nasopharynx.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  AJR. American journal of roentgenology     Volume:  193     ISSN:  1546-3141     ISO Abbreviation:  AJR Am J Roentgenol     Publication Date:  2009 Nov 
Date Detail:
Created Date:  2009-10-21     Completed Date:  2009-12-03     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7708173     Medline TA:  AJR Am J Roentgenol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1318-23     Citation Subset:  AIM; IM    
Affiliation:
Department of Diagnostic Radiology, MRI Section, University of Greifswald, Mecklenburg Vorpommern, Germany. kuehn@uni-greifswald.de
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Abdomen / pathology*
Adult
Aged
Aged, 80 and over
Contrast Media
Female
Gadolinium DTPA / diagnostic use*
Humans
Image Enhancement
Image Interpretation, Computer-Assisted
Magnetic Resonance Imaging / methods*
Male
Middle Aged
Organometallic Compounds / diagnostic use*
Statistics, Nonparametric
Chemical
Reg. No./Substance:
0/Contrast Media; 0/Organometallic Compounds; 0/gadolinium ethoxybenzyl DTPA; 138071-82-6/gadobutrol; 80529-93-7/Gadolinium DTPA

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Intraabdominal Complications Secondary to Ventriculoperitoneal Shunts: CT Findings and Review of the...
Next Document:  The Actual Role of CT and Ventilation-Perfusion Scanning in Workup for Suspected Pulmonary Embolism:...